The exact treatment for PE depends on its severity and whether you need critical treatment in an emergency room setting. PE medications are usually considered before medical procedures.

The trial adds much-needed randomized data to an area where it’s been lacking. Questions about methods muddy interpretation.

(Nasdaq:NARI) today announced positive results from its prospective PEERLESS trial for the FlowTriever system.

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) recently awarded a $3.7 ...

Penumbra (NYSE:PEN) today announced new data demonstrating improved outcomes with its computer-assisted vacuum thrombectomy ...

KKR's acquisition of SunFireMatrix and Consello's purchase of EHE Health are among the deals that exemplify the new trends.

Thrombolex announced findings from the RESCUE-II trial, which is evaluating the company’s Bashir endovascular catheter to ...

Penumbra (PEN) announced new data that demonstrate patients with intermediate-risk pulmonary embolism – PE – treated with ...

Findings from the first international randomized controlled trial to compare patient outcomes following treatment with ...

Primary endpoint win driven by both hard clinical outcomes and hospital resource utilizationIRVINE, Calif., Oct. 29, 2024 ...

A nationwide retrospective study evaluated health care resource utilization and outcomes among patients with ...